In vitro impact of anti-immunoglobulin E monoclonal antibodies, including omalizumab on whole blood basophil histamine release: Assessment of direct induction of basophil histamine release and evaluation of modulation of allergen-induced basophil histamine release

Abstract

There was no evidence that humanized, monoclonal anti-IgE antibodies E25 (omalizumab), E27, or QGE031 directly or indirectly induced histamine release from peripheral blood basophils.

Atopy, asthma, and the elderly: A paradigm for personalized therapy

“…However, regardless of age, omalizumab has been associated with a low but significant incidence of anaphylactic events, the pathophysiologic nature of which remains unknown. To elucidate the mechanisms of this adverse drug reaction, Kowal et al 2 evaluated the potential pathogenetic role of anti-IgE and/or anti-IgEIgE immune complexes to release histamine from peripheral blood basophils. In addition, they sought to determine whether anti-IgE-IgE complexes could potentially modulate allergen-mediated activation of peripheral blood basophils.…”